These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 31197835)

  • 21. Trends in the use and outcomes of implantable cardioverter-defibrillators in patients undergoing dialysis in the United States.
    Charytan DM; Patrick AR; Liu J; Setoguchi S; Herzog CA; Brookhart MA; Winkelmayer WC
    Am J Kidney Dis; 2011 Sep; 58(3):409-17. PubMed ID: 21664735
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluating sex differences in population-based utilization of implantable cardioverter-defibrillators: role of cardiac conditions and noncardiac comorbidities.
    MacFadden DR; Tu JV; Chong A; Austin PC; Lee DS
    Heart Rhythm; 2009 Sep; 6(9):1289-96. PubMed ID: 19695966
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Primary Prevention Implantable Cardioverter Defibrillators in Patients With Nonischemic Cardiomyopathy: A Meta-analysis.
    Al-Khatib SM; Fonarow GC; Joglar JA; Inoue LYT; Mark DB; Lee KL; Kadish A; Bardy G; Sanders GD
    JAMA Cardiol; 2017 Jun; 2(6):685-688. PubMed ID: 28355432
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Real world effectiveness of primary implantable cardioverter defibrillators implanted during hospital admissions for exacerbation of heart failure or other acute co-morbidities: cohort study of older patients with heart failure.
    Chen CY; Stevenson LW; Stewart GC; Bhatt DL; Desai M; Seeger JD; Williams L; Jalbert JJ; Setoguchi S
    BMJ; 2015 Jul; 351():h3529. PubMed ID: 26174233
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapy optimization in patients with heart failure: the role of the wearable cardioverter-defibrillator in a real-world setting.
    Röger S; Rosenkaimer SL; Hohneck A; Lang S; El-Battrawy I; Rudic B; Tülümen E; Stach K; Kuschyk J; Akin I; Borggrefe M
    BMC Cardiovasc Disord; 2018 Mar; 18(1):52. PubMed ID: 29544442
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Primary prevention of sudden cardiac death by implantable cardioverter-defibrillator therapy in Chinese patients with heart failure: a single-center experience.
    Chen TB; Cheng KA; Gao P; Cheng ZW; Fan JB; Jiang XC; Fang Q
    Chin Med J (Engl); 2010 Apr; 123(7):848-51. PubMed ID: 20497676
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Primary prevention implantable cardioverter defibrillators in end-stage kidney disease patients on dialysis: a matched cohort study.
    Pun PH; Hellkamp AS; Sanders GD; Middleton JP; Hammill SC; Al-Khalidi HR; Curtis LH; Fonarow GC; Al-Khatib SM
    Nephrol Dial Transplant; 2015 May; 30(5):829-35. PubMed ID: 25404241
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Deactivation of implantable cardioverter-defibrillators: results of patient surveys.
    Herman D; Stros P; Curila K; Kebza V; Osmancik P
    Europace; 2013 Jul; 15(7):963-9. PubMed ID: 23447573
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of primary prevention implantable cardioverter-defibrillators in a population-based cohort is associated with a significant survival benefit.
    Parkash R; Sapp JL; Basta M; Doucette S; Thompson K; Gardner M; Gray C; Brownell B; Kidwai H; Cox J
    Circ Arrhythm Electrophysiol; 2012 Aug; 5(4):706-13. PubMed ID: 22685111
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sudden cardiac death: New approaches for implantable cardioverter-defibrillators (ICDs).
    Cappato R; Ali H
    Int J Cardiol; 2017 Jun; 237():38-41. PubMed ID: 28377192
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The implantable cardioverter-defibrillator and hypertrophic cardiomyopathy. Experience at three centers].
    Marín F; Gimeno JR; Payá E; García-Alberola A; Pérez-Alvarez L; Fernández X; de la Morena G; Sogorb F; Castro-Beiras A; Valdés M; Martínez JG; Monserrat L
    Rev Esp Cardiol; 2006 Jun; 59(6):537-44. PubMed ID: 16790196
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Time dependence of risks and benefits in pediatric primary prevention implantable cardioverter-defibrillator therapy.
    DeWitt ES; Triedman JK; Cecchin F; Mah DY; Abrams DJ; Walsh EP; Gauvreau K; Alexander ME
    Circ Arrhythm Electrophysiol; 2014 Dec; 7(6):1057-63. PubMed ID: 25262116
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of beta-blockers in patients with an implantable cardioverter defibrillator.
    LaPointe NM; Stafford JA; Pappas PA; Al-Khatib SM; Anstrom KJ
    Ann Pharmacother; 2009 Jul; 43(7):1189-96. PubMed ID: 19567655
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Age and Outcomes of Primary Prevention Implantable Cardioverter-Defibrillators in Patients With Nonischemic Systolic Heart Failure.
    Elming MB; Nielsen JC; Haarbo J; Videbæk L; Korup E; Signorovitch J; Olesen LL; Hildebrandt P; Steffensen FH; Bruun NE; Eiskjær H; Brandes A; Thøgersen AM; Gustafsson F; Egstrup K; Videbæk R; Hassager C; Svendsen JH; Høfsten DE; Torp-Pedersen C; Pehrson S; Køber L; Thune JJ
    Circulation; 2017 Nov; 136(19):1772-1780. PubMed ID: 28877914
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Determinants of patient survival rate after implantation of a cardioverter-defibrillator without resynchronisation capability.
    Lelakowski J; Piekarz J; Rydlewska A; Majewski J; Senderek T; Ząbek A; Małecka B
    Kardiol Pol; 2012; 70(11):1099-110. PubMed ID: 23180517
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characteristics and Outcomes of Pediatric Patients Who Undergo Placement of Implantable Cardioverter Defibrillators: Insights From the National Cardiovascular Data Registry.
    Baskar S; Bao H; Minges KE; Spar DS; Czosek RJ
    Circ Arrhythm Electrophysiol; 2018 Sep; 11(9):e006542. PubMed ID: 30354291
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Trends in hospitalization for the implantation of cardioverter-defibrillators in the United States, 1990-2005.
    Brown DW; Croft JB; Greenlund KJ; Mensah GA; Giles WH
    Am J Cardiol; 2008 Jun; 101(12):1753-5. PubMed ID: 18549853
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sex differences in the use of implantable cardioverter-defibrillators for primary and secondary prevention of sudden cardiac death.
    Curtis LH; Al-Khatib SM; Shea AM; Hammill BG; Hernandez AF; Schulman KA
    JAMA; 2007 Oct; 298(13):1517-24. PubMed ID: 17911496
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Survival After Secondary Prevention Implantable Cardioverter-Defibrillator Placement: An Analysis From the NCDR ICD Registry.
    Katz DF; Peterson P; Borne RT; Betz J; Al-Khatib SM; Varosy PD; Wang Y; Hsu JC; Hoffmayer KS; Kipp RT; Hansen CM; Turakhia MP; Masoudi FA
    JACC Clin Electrophysiol; 2017 Jan; 3(1):20-28. PubMed ID: 29759690
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Specific indications and clinical outcome in patients with subcutaneous implantable cardioverter-defibrillator (ICD) - A nationwide multicentre registry.
    Sponder M; Khazen C; Dichtl W; Fiedler L; Mörtl D; Teubl A; Steinwender C; Martinek M; Nürnberg M; Dalos D; Kastner J; Schukro C
    Eur J Intern Med; 2018 Feb; 48():64-68. PubMed ID: 28978409
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.